Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

764.80INR
3:51pm IST
Change (% chg)

Rs-5.35 (-0.69%)
Prev Close
Rs770.15
Open
Rs766.20
Day's High
Rs773.75
Day's Low
Rs763.40
Volume
2,342,694
Avg. Vol
3,340,677
52-wk High
Rs933.95
52-wk Low
Rs704.00

SUN.NS

Chart for SUN.NS

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.28
Market Cap(Mil.): Rs1,853,562.00
Shares Outstanding(Mil.): 2,406.75
Dividend: 1.00
Yield (%): 0.13

Financials

  SUN.NS Industry Sector
P/E (TTM): 30.03 36.26 36.23
EPS (TTM): 25.65 -- --
ROI: -- 14.29 13.79
ROE: -- 15.13 14.74

EU court to rule on drugmaker Lundbeck's pay-for-delay deals

BRUSSELS, Sept 6 Europe's top court will rule on Thursday whether Danish drugmaker Lundbeck breached EU antitrust rules by paying smaller rivals to delay generic copies of its blockbuster citalopram anti-depressant from entering the market.

06 Sep 2016

Sun Pharma first-quarter profit boosted by Gleevec generic

MUMBAI Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States.

12 Aug 2016

India's Sun Pharma Q1 profit boosted by Gleevec generic

MUMBAI, Aug 12 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States.

12 Aug 2016

BUZZ-India's Sun Pharma rises on U.S. FDA nod for generic diabetes drug

** Sun Pharmaceutical Industries rises as much as 1.4 pct after the drugmaker gets approval from U.S. health regulators for its generic version of Glumetza tablets, which treat type 2 diabetes

02 Aug 2016

BUZZ-India's Sun Pharma up; Co signs licence deal for Psoriasis treatment

** Shares of Indian drugmaker Sun Pharmaceutical Industries rise as much as 2.36 pct to their highest in nearly two months

28 Jul 2016

Exclusive: Teva, Mylan eye Pfizer's Brazil venture, sources say

SAO PAULO Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said.

26 Jul 2016

Teva, Mylan eye Pfizer's Brazil venture, sources say

SAO PAULO Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said.

26 Jul 2016

BUZZ-India's Sun Pharma down; gains in early trade on share buyback

** Shares of Sun Pharmaceutical Industries rise as much as 1.65 pct in early trade, but down 0.5 pct as of 0552 GMT

24 Jun 2016

India's Sun Pharma enters dermatology segment to expand retail offering

MUMBAI, June 8 India's Sun Pharmaceutical Industries Ltd said on Wednesday it had entered the dermatology segment as part of an initiative to further expand its retail offerings.

08 Jun 2016

Morning News Call - India, June 1

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_06012016.pdf FACTORS TO WATCH 10:30 am: Federal cabinet likely to meet in New Delhi. Agenda not given. GMF: ASIA LIVECHAT - MARKETS FOCUS with Michael Every, Head of Financial Markets Research-Asia-Pacific, Rabobank Lots happening in Asia. While China seems to have cooled down a bit, we have the the BOJ piling on suprises nearly every policy meet. Also

01 Jun 2016

Earnings vs. Estimates